This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ozaki, I. Articles by Yamamoto, K. Search for Related Content PubMed PubMed Citation Articles by Ozaki, I. Articles by Yamamoto, K.

Menatetrenone, a Vitamin K2 Analogue, Inhibits Hepatocellular Carcinoma Cell Growth by Suppressing Cyclin D1 Expression through Inhibition of Nuclear Factor B Activation

Authors' Affiliations: ¹ Division of Hepatology and Metabolism, Department of Internal Medicine, and ² Health Administration Center, Saga Medical School, Saga University, Nabeshima, Saga, Japan; ³ Second Department of Surgery, China Medical University, Heping District, Shenyang, China; and ⁴ Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia

Requests for reprints: Iwata Ozaki, Health Administration Center, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan. Phone: 81-952-34-3215; Fax: 81-952-34-2017; E-mail: ozaki{at}cc.saga-u.ac.jp.

Purpose: Menatetrenone, a vitamin K2 analogue, plays an important role in the production of blood coagulation factors. Menatetrenone has also bee shown to have antineoplastic effects against several cancer cell lines including hepatocellular carcinoma (HCC) cells. However, the mechanisms by which vitamin K2 inhibits HCC cell growth have not bee fully clarified, and we therefore investigated the molecular basis of vitamin K2–induced growth inhibition of HCC cells.

Experimental Design: HCC cells were treated with vitamin K2 and the expression of several growth-related genes including cyclin-dependent kinase inhibitors and cyclin D1 was examined at the mRNA and protein levels. A reporter gene assay of the cyclin D1 promoter was done under vitamin K2 treatment. The regulation of nuclear factor B (NF-B) activation was investigated by a NF-B reporter gene assay, an electrophoretic mobility shift assay, a Western blot for phosphorylated IB, and an in vitro kinase assay for IB kinase (IKK). We also examined the effect of vitamin K2 on the growth of HCC cells transfected with p65 or cyclin D1.

Results: Vitamin K2 inhibited cyclin D1 mRNA and protein expression in a dose-dependent manner in the HCC cells. Vitamin K2 also suppressed the NF-B binding site-dependent cyclin D1 promoter activity and suppressed the basal, 12-O-tetradecanoylphorbol-13-acetate (TPA)–, TNF-–, and interleukin (IL)-1–induced activation of NF-B binding and transactivation. Concomitant with the suppression of NF-B activation, vitamin K2 also inhibited the phosphorylation and degradation of IB and suppressed IKK kinase activity. Moreover, HCC cells overexpressing cyclin D1 and p65 became resistant to vitamin K2 treatment.

Conclusion: Vitamin K2 inhibits the growth of HCC cells via suppression of cyclin D1 expression through the IKK/IB/NF-B pathway and might therefore be useful for treatment of HCC.